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Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of
cyclosporin G versus cyclosporin A. Cyclosporin G (CsG) is an analogue
of cyclosporin A (CsA) with strong immunosuppressive activity. We
compared these two drugs in a rat model in which salt depletion
promotes irreversible renal interstitial fibrosis with renal dysfunction in
animals given CsA for three weeks. When both drugs were given in the
same dosage on a weight basis (15 mg/kg/day, subcutaneously), CsA
blood levels were higher than CsG (3305 vs. 1824 ng/ml, P < 0.001).
This could be explained by a higher CsG clearance (6.4 vs. 4.3
mi/mm/kg in CsA, P < 0.0001) resulting in smaller CsG area under the
curve. There was also lower renal and hepatic CsG tissue concentra.
tions. CsA induced a dramatic decrease in GFR, 0.14 in CsA versus
0.67 ml/min/100 g in control, P < 0.001, and increased urinary excretion
of N-acetyl /3-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in
control rats, P < 0.001. CsG-treated and control rats had similar GFR
and urinary NAG. When CsA dosage was decreased to 7.5 mg/kg blood
levels were similar to those found with CsG 15 mg/kg. CsA at this dose
caused a reduced GFR (0.29 ml/min/l00 g) and an increased urinary
NAG (20 IU/gCr) (P < 0.01 vs. control for both). Both dosages of CsA
induced considerable cortical and medullary injury (interstitial fibrosis
and tubular atrophy), more severe than the histological damage found in
CsG-treated rats. Neither drug promoted significant changes in liver
function or histology. These results demonstrate that CsG caused less
renal interstitial fibrosis and functional changes than CsA when the
drugs were given at the same dosage or when similar blood levels of
each drug were achieved.
Cyclosporin A (CsA) has more than 700 analogues, but few
have significant immunosuppressive activity [1]. Cyclosporin G
(CsG) or Nva-2 cyclosporine is a natural analogue of cyclospo-
rifle with strong immunosuppressive activity in which L-norva-
line has replaced aipha-aminobutyric acid in position 2. In vitro
and in vivo immunological studies have shown similar immuno-
suppressive efficacy between CsA and CsG [2—5]. In renal and
heart transplantation in rats CsG has been shown to be as
effective as CsA at doses of 10 mg/kg/day or more [6—8].
Preliminary results of clinical trials comparing CsA and CsG
immunosuppressive efficacy in solid-organ transplantation dem-
onstrated similar outcomes of patient and graft survival [9—11].
The nephrotoxicity of CsA and CsG has been compared with
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conflicting results [2, 3, 8—20]. Hepatotoxicity has been re-
ported in experimental animals [3, 15, 18, 20] or patients given
CsG [9—11, 191.
In this study we compared the toxicity and pharmacokinetics
of CsA and CsG in an experimental model of chronic cyclo-
sporine-induced nephropathy. In this model, rats given CsA on
a salt-depleted diet develop severe decreases in glomerular
filtration rate as well as irreversible striped tubulointerstitial
injury similar to the histological lesion found in human chronic
CsA-induced nephrotoxicity [21, 22].
Methods
Animals
Adult male Sprague-Dawley rats (Charles River, Wilmington,
Massachusetts, USA) weighing 250 g were housed in individual
cages in a temperature- and light-controlled environment. They
received a salt-free boiled rice diet (8.5% of protein, 76.6% of
carbohydrate, less than 4.3% of fat, enriched with ferric or-
thophosphate and thiamine mononitrate) and were allowed free
access to tap water.
Drugs
CsA and CsG (Sandoz Research Institute, East Hanover,
New Jersey, USA) were dissolved in anhydrous ethanol
(12.5%) and mixed with olive oil (87.5%) to a final concentration
of 7.5 mg/mi and 15 mg/mi of CsA, and 15 mg/ml and 25 mg/mI
of CsG.
Basic protocol
The rats received one intraperitoneal injection of furosemide
(4 mg/kg) and started the rice diet. After one week weight-
matched pairs of rats were randomly assigned to receive a daily
subcutaneous injection of CsA 15 mg/kg (CsA15, N = 20), CsG
15 mg/kg (CsG15, N = 21) or an identical volume of vehicle
(VH, N = 27). In order to obtain similar blood levels of CsA and
CsG, an additional group of rats were randomized to receive
CsA 7.5 mg/kg (CsA7.5, N = 15) or CsG 25 mg/kg (CsG25, N =
13). Body weight was measured daily throughout the experi-
ment. After three weeks of treatment on rice diet the rats had
the tail blood pressure (BP) measured with a plethysmograph
(Narco Bio-systems, Houston, Texas, USA) and were placed in
metabolic cages (Nalge Company, Rochester, New York, USA)
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for urine collection. After 24 hours, a blood sample was drawn
and, as previously designated for each rat, the glomerular
filtration rate (GFR) was measured by '4C-inulin clearance or
the left kidney was collected for histology after in situ perfu-
sion.
Inulin clearance
After anesthesia polyethylene tubes (PE-50) were placed in
the jugular vein for blood collection and in the femoral vein for
infusion. A polyethylene tube (PE-90) was also placed and
sutured in the bladder. A loading dose of 0.25 Ci '4C-inulin in
6 ml 1% NaHCO3 was given followed by a maintenance infusion
of 2.5 Ci 14C-inulin in 10 ml 1% NaHCO3 at a rate of 52 1.dlmin.
After a 30-minute equilibration time, urine was collected over
four periods of at least 20 minutes each in preweighed vials. A
blood sample (0.35 ml) was drawn at the midpoint of each urine
collection and replaced with an equal volume of 1% NaHCO3.
Inulin clearances values expressed as ml/min/l00 g body wt
represent the mean of the four clearance periods. After the end
of the inulin clearance the rat was euthanized, the left kidney
was removed and weighed.
In situ perfusion
After anesthesia the rat received 500 U of heparin i.v. and a
ventral midline incision was made exposing the abdominal
aorta, posterior vena cava, left and right renal vessels. The
aorta and vena cava just above the bifurcation to the legs plus
the mesenteric and right kidney arteries were tied. A ligature
was loosely tied around the aorta and vena cava above the renal
arteries. An 18-gauge needle was introduced in the abdominal
aorta pointing towards the kidneys. An infusion of 10 ml of
saline was started at the same time as the ligature above the
renal arteries was tied and a hole was made in the left renal
vein. After the saline flush, six minutes of perfusion with 1%
glutaraldehyde in a modified 3/4 Tyrode buffer was done. The
pressure in the system was kept stable at 140 to 160 mm Hg and
the flow at 10 to 12 mI/mm. After the perfusion the left kidney
was removed, weighed and placed in a vial with the perfusion
solution.
Renal histology
The renal tissue was processed, embedded in plastic and cut
at I p. as in previous studies [21, 22]. The extent of tubuloin-
terstitial injury (fibrosis and tubular atrophy) was evaluated
semi-quantitatively (0 to 4+) in a blinded way (Dr. S. Rosen).
Approximately six sections (3 x 3 mm) were analyzed per
animal. These sections included both horizontal and the tradi-
tional sagittal sections. Interstitial fibrosis and tubular atrophy
in the cortex was first seen predominantly in the medullary ray.
These first recognizable changes were graded as trace. As the
injury involved the medullary ray more extensively, the
changes were considered 1+. When the medullary ray changes
were widespread, a 2+ grade was given. With increasing
degrees of fibrosis, the labyrinth was involved and depending
on the extent, the grades were 3 or 4+. In the medulla, the first
changes related to tubular atrophy were often associated with
casts. Initially, these alterations were unaccompanied by fi-
brotic change. Occasional atrophic tubules were graded trace.
As the changes became more extensive, a grade 1+ was given.
When the process became somewhat diffuse, a 2+ score was
given. At this time, a fibrotic component began to be seen.
Higher scores depended on further increases in atrophic change
and the degree of accompanying fibrosis.
Liver histology
Liver specimens were fixed in 10% neutral buffered formalin
and processed and embedded in paraffin using standard tech-
niques. Histologic sections, 5 p. in thickness, were cut from the
paraffin block and stained with hematoxylin and eosin, Mal-
lory's trichrome, and periodic acid-Schiff's stain following
diastase digestion. The sections were examined and morpho-
logic features assessed without knowledge of the experimental
manipulation (Dr. Randall G. Lee).
Pharmacokinetic study
CsA and CsG solutions were prepared diluting the drug with
ethanol (12.5%) and intralipid (87.5%) (KabiVitrum, Clayton,
North Carolina, USA) to a final concentration of 15 mglml. Rats
weighing 300 g were kept for seven days on rice diet and in the
eighth day polyethylene tubes (PE-50) were placed in both
jugular veins and CsA (N = 6) or CsG (N = 7)15 mg/kg was
given by the left jugular vein over an average time of one
minute. Blood samples were drawn from the right jugular vein
at 2, 5, 15, 30, 60, 120, 180, 360 and 1440 minutes after the
infusion of the drug. Animals were kept under light anesthesia
throughout the procedure. CsA and CsG concentration versus
time data were analyzed using noncompartmental analysis. The
elimination rate constant (kel) was determined as the terminal
slope of the linear least-squares regression line of a semiloga-
rithmic plot of concentration versus time data. Area under the
concentration versus time curve (AUC) was calculated by the
linear trapezoidal rule and extrapolated to infinity (AUC0OO).
The terminal area was determined by dividing the last measured
concentration by the terminal slope (kel). Noncompartmental
analysis was used to calculate total body clearance (CL) and
apparent volume of distribution (Varea)according to the follow-
ing equations:
CL = Dose/AUC0
Varea = CL/kel
Half-life (t112) was calculated by the equation t112 = 0.693/kel.
Tissue concentrations of cyclosporine
Rats kept on rice diet were given CsA (N = 5) or CsG (N =
4) s.c. as already described. After three weeks of treatment the
animals were euthanized and kidney and liver samples were
collected. The tissue was weighed and homogenized with 3 ml
of methanol (50°C) in a glass jar with Teflon. Tissue homoge-
nized was centrifuged at 3000 x g during 10 minutes (room
temperature) and the supernatant was saved. Then, 3 ml of
methanol was added again to the tissue and the procedure
repeated. The total obtained supematant was dried under
nitrogen and saved at —20°C to further analysis. Kidney and
liver samples from a rat given only the vehicle were used as
control.
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Table 1. Daily variation of body weight, kidney weight, urinary
volume and blood pressure after a three week treatment with vehicle,
CsA or CsG on rice diet
Body wt
glday
Kidney
wt/lOO g
UV
ml/24 hr
BP
mm Hg
VH 1.49 0.18
(27)
0.42 0.01
(24)
27.7 2.3
(27)
116.9 3.7
(22)
CsA 15 mg 0.86 0.14
(20)
0.41 0.01
(20)
22.5 2.5
(20)
116.6 3.8
(15)
CsG 15mg 1.33 0.13
(21)
0.43 0.01
(21)
20.9 1.6
(20)
118.9 3.4
(16)
Data are presented as mean sEM; Number of rats are in parenthe-
ses. Abbreviations are: iBody wt, variation in body weight; Kidney wt,
kidney weight; UV, urinary volume; BP, blood pressure; VH, vehicle.
a P < 0.05 vs. VH
Analytical methods
Urinary and serum sodium and potassium were measured by
flame photometer (Instrumentation Laboratories, Lexington,
Massachusetts, USA). Urinary and serum creatinine, urinary
and serum magnesium, serum aspartate aminotransferase
(AST), serum alanine aminotransferase (ALT), serum total
bilirubin (TB) and urinary N-acetyl /3-D-glucosaminidase
(NAG) were measured by a Cobas autoanalyzer (Roche Diag-
nostics, Hoffman-La Roche Division, Nutley, New Jersey,
USA). Urinary enzymes results were normalized by the urinary
creatinine concentration. Cyclosporine whole-blood levels and
tissue levels were determined by a specific CsA monoclonal
radioimmunoassay (Incstar Corp., Stillwater, Minnesota,
USA). CsA antibody has been shown to have equal affinity for
CsA and CsG and monoclonal radioimmunoassay have given
results comparable to HPLC [1, 23]. Serum and urine radioac-
tivity were measured by a Beckman LS 100 liquid scintillation
counter (Beckman Instruments, Palo Alto, California, USA).
The clearance of inulin (GFR), clearance of creatinine (Car),
fractional excretion of sodium (FENa), fractional excretion of
potassium (FEK) and fractional excretion of magnesium (FEM5)
were calculated by the standard formulas.
Statistical analysis
Results are presented as mean SEM. Comparisons between
CsA and CsG in the pharmacokinetic and cyclosporine tissue
concentration analysis were done by two-tailed unpaired Stu-
dent's f-test or Mann-Whitney test, as appropriate. Multiple
comparisons were done by ANOVA followed by Tukey-
Kramer test or by Kruskal-Wallis test followed by Dunn's test,
as appropriate. The level of statistical significance was chosen
as P < 0.05.
Results
Rats given CsA gained less body weight than those receiving
only vehicle (P < 0.05), while the daily variation in body weight
was similar between CsG and vehicle animals. There were no
differences in kidney weight, blood pressure or urinary volume
among the three groups (Table 1).
Twenty-four-hour trough cyclosporine blood levels
When CsA and CsG were given in the same dosage on a
weight basis the CsA blood level was almost two times higher
Fig. 1. Comparison between cyclosporine blood levels (CSBL) and
glomerular filtration rate decrease after three week treatment with CsA
15 and 7.5 mg/kg or CsG 15 and 25 mg/kg. *p < 0.05 vs. CsA 15 mg/kg.
than the CsG blood level (P < 0.001, CsA1S vs. CsG15). The
increase of CsG daily dosage to 25 mg/kg resulted in cyclospo-
rifle blood level similar to that found with CsG 15 and therefore
still lower than CsA1S (P < 0.001). We only achieved compa-
rable blood level between CsA and CsG when the CsA daily
dosage was decreased to 7.5 mg/kg, which resulted in a cyclo-
sporine blood level similar to that found for CsG 15 and signif-
icantly lower than the CsA1S value (P < 0.001; Fig. 1).
Renal function
Rats given CsA had a lower GFR (P < 0.01, CsA7.5 vs. VH
and P < 0.001, CsA15 vs. VH), lower Cr (P < 0.001, CsA7.5
vs. VH and CsA15 vs. VH) and higher serum creatinine (P <
0.05, CsA7.5 vs. VH and P < 0.001, CsAl5 vs. VH) as
compared to control animals. There were no significant differ-
ences in renal function between CsG and control rats. How-
ever, when CsA and CsG rats were compared CsA-treated
animals showed a lower GFR (P < 0.05, CsAl5 vs. CsG15 and
P < 0.01, CsA15 vs. CsG2S), lower Cci (P < 0.05, CsA7.5 VS.
CsGL5 and CsA15 vs. CsG2S and P < 0.01, CsA1S vs. CsGl5)
and higher serum creatinine (P < 0.001, CsAl5 vs. CsG15) than
CsG rats (Table 2).
The urinary excretion of N-acetyl f3-D-glucosaminidase was
significantly higher in CsA animals as compared to vehicle (P <
0.01, CsA7.5 vs. VH and P < 0.001, CsA1S vs. VH) or CsG rats
(P < 0.05, CsA7.5 vs. CsG15 and P < 0.01, CsA15 vs. CsGL5;
Table 2).
Serum sodium and FENa were similar among groups. The
FENa was virtually zero reflecting the severe dietary sodium
restriction. Although serum potassium was higher in CsG group
(P < 0.05 vs. VH), FEK was elevated in CsA-treated rats (P <
0.05 vs. VH). Both CsA and CsG rats showed decreased serum
magnesium as compared to control animals (P < 0.001, CsA15
vs. VH and P < 0.05, CsG15 vs. VH) and FEMg higher than that
found for vehicle-treated animals. Nevertheless, the differences
in FEMg were not statistically significant (Table 3).
Renal histology
The most striking histological changes in cyclosporine-
treated animals were interstitial fibrosis and tubular atrophy.
The injury was most pronounced in the medullary ray, giving
the characteristic striped appearance and in the inner stripe of
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Table 2. Glomerular function, renal histology score and NAG enzymuria after a three-week treatment with vehicle, CsA or CsG on rice diet
GFR Ce,. sCr
rng/dl
CIFS MIFS NAG/Ur
lUig Crin/100 gmi/rn 0 to 4+
VH 0.67 0.06
(11)
0.431 0.021
(27)
0.55 0.02
(27)
0.08 0.04
(13)
0.02 0.02
(12)
13.0 1.0
(27)
CsA 7.5 mg 0.29 O.06a
(7)
0.264 O.021a
(14)
0.72 O.05a
(15)
1.68 0.21
(7)
1.71 O.15
(7)
20.4 i.r
(14)
CsA 15 mg 0.14 0.04a 0.256 0.017a 0.87 0.05a 1.08 0.l5a 1.15 0.27a 20.9 l.6
CsG 15 mg
CsG 25 mg
(10)
0.43 009b
(9)
0.53 009b
(8)
(19)
0.370 0023b.c
(19)
0.354 0021b
(Il)
(19)
0.65 0.07k'
(20)
0.66 0.05
(11)
(6)
0.40 0.06
(11)
0.20 0.05"
(5)
(5)
0.36 0b.c
(11)
0.50 0.34c
(4)
(20)
14.1 l.4
(21)
18.1 1.6
(13)
Data are presented as: mean sEas; number of rats are in parentheses. Abbreviations are: GFR, glomerular filtration rate; CCr, clearance of
creatinine; Scr, serum creatinine; CIFS, cortical interstitial fibrosis score; MIFS, medullar interstitial fibrosis score; Ucr, urinary creatinine; VH,
vehicle.
ap<005vs VH
b P < 0.05 vs. CsA 15 mg
P < 0.05 vs. CsA 7.5 mg
Table 3. Serum electrolytes and fractional excretion of sodium, potassium and magnesium after a three-week treatment with vehicle, CsA, or
CsG on rice diet
SN8
mEq/liter
FENa
%
SK
mEq/liter
FEK
%
SMg
rng/di
FEEs
%
VH 145 2
(24)
0.0001 0.0001
(24)
5.3 0.2
(24)
7.7 0.6
(24)
2.9 0.1
(20)
1.0 0.2
(11)
CsA 15 mg 141 2
(16)
0.0015 0.0010
(16)
5.7 0.2
(16)
11.0 1.2k
(16)
2.3 0.1
(16)
2.2 0.5
(14)
CsG 15 mg 141 2
(17)
0.0016 0.0011
(17)
6.0 0.2a
(17)
8.0 1.0
(17)
2.5 0.28
(12)
1.7 0.4
(8)
Data are mean SEM; Number of rats are in parentheses. Abbreviations are: SNa, serum sodium; FENa, fractional excretion of sodium; SK,
serum potassium; FEK, fractional excretion of potassium; SMg, serum magnesium; FEMS, fractional excretion of magnesium; VH, vehicle.
ap <o5 vs. VH
the outer medulla. Glomerular sclerosis and vascular injury
were not observed. Juxtaglomerular apparatus hyperplasia
seemed present in all animals, probably due the low salt diet,
and was not more strikingly evident in cyclosporine-treated
animals.
CsA-treated rats had a higher cortical injury score than vehicle
(P < 0.001, CsA7.5 vs. VH and CsA15 vs. VH) or CsG-treated
rats (P < 0.001, CsA7.5 vs. CsG15, CsA15 vs. CsGl5, CsA7.5 vs.
CsG25 and CsA15 vs. CsG2S). CsA animals also showed a higher
medullary injury score than vehicle (P < 0.001, CsA7.5 vs. VH
and CsA15 vs. VH) or CsG animals (P < 0.001, CsA7.5 vs.
CsG15;P <0.01, CsA15 vs. CsG15; andP <0.001, CsA7.5 vs.
CsG25). Although the interstitial fibrosis score of CsG-treated
rats was higher than that found in control animals the difference
did not achieve statistical significance (Table 2, Fig. 2).
Liver function and histology
The values of AST and ALT of either CsA or CsG animals
were not increased as compared to animals receiving vehicle.
Both CsA and CsG rats presented increased TB as compared to
control animals. Nevertheless, this difference was not statisti-
cally significant (Table 4).
Liver histology was consistently normal or showed mild fatty
changes, without differences between cyclosporine- or vehicle-
treated animals (Table 4).
Pharmacokineric study
CsG had a higher clearance than CsA resulting in lower
trough blood levels. There was also smaller area under the
curve, higher volume of distribution and lower renal and
hepatic levels of CsG. While CsA treated rats had similar renal
and hepatic tissue cyclosporine levels, CsG-treated animals had
cyclosporine liver tissue levels two times higher as compared to
the renal tissue levels (Table 5, Fig. 3).
Discussion
The price for the widespread and prolonged use of CsA, even
with therapeutic drug monitoring, is its chronic nephrotoxicity.
The therapeutic window, if one truly exists, is narrow and some
degree of renal dysfunction is the general rule when glomerular
filtration rate is the renal parameter measured [24]. Several
approaches have been tried to bypass these problems, including
a search for safer yet effective cyclosporine analogues. In 1985,
Hienstand and colleagues reported that cyclosporin G (CsG) or
Nva-2 cyclosporine had similar immunosuppression activity but
less nephrotoxicity than CsA in rats [2]. The enthusiasm about
CsG was tempered by the conflicting results following the initial
report. Comparison among the different studies is difficult since
animal species, strain, dosage, route of administration and
duration of treatment were not uniform. Most authors have
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Fig. 2. Rena! cortex of rats given CsG
(A) or CsA (B), 15 mg/kg during 3
weeks. In rats treated with CsG only
slight interstitial fibrosis and tubular
atrophy are seen related to a medullary
ray (center). When CsA is given, the
interstitial fibrosis and tubular atrophy
are much more extensive. x75, x75.
used only serum creatinine or creatinine clearance to measure
renal function. Trough cyclosporine blood levels of CsA and
CsG have not always been measured and when they were
different no attempt was made to obtain comparable blood
concentrations. Finally, it is not known if CsG induces chronic
tubulointerstitial damage to the same extent as CsA. In this study
we took advantage of an experimental model of cyclosporine-
induced chronic nephrotoxicity in salt-depleted rats to compare
CsA and CsG using both similar doses on a weight basis and
similar trough blood levels of the two drugs.
While CsA produced a major decrease in GFR and creatinine
clearance and increased serum creatinine, CsG-treated rats had
renal function similar to control animals. These results are
consistent with previous studies which also found increased
serum creatinine in CsA but not CsG-treated rats after three or
more weeks of treatment [12, 15, 16]. Duncan et a!, using
Sprague-Dawley rats, found a slight but significant increase in
serum creatinine and decrease in Ce,, with both CsG and CsA.
However, these changes were more marked in CsA rats and
CsG-treated rats had Ccr significantly higher than CsA animals
[3]. Only two other studies have measured GFR by inulin
clearance to assess renal function in comparative studies. One
found decreased GFR and renal plasma flow (RPF) in CsA but
not CsG rats after three weeks of cyclosponne treatment and in
the other the acute intravenous infusion of either CsA or CsG in
rats promoted similar falls in GFR and RPF [13, 14]. An elegant
study by Rooth et a! demonstrated that CsA infusion in mice
induced an almost complete inhibition of subcapsular blood
flow. CsG only decreased blood flow at high infusion rates, but
the inhibition was still significantly below that produced by CsA
[25]. in vitro studies showed that CsG was less toxic than CsA
to LLC-PK cells [26]. Preliminary results of clinical trials in
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Table 4. Liver enzymes and total bilirubin after a three-week
treatment with vehicle, CsA or CsG on rice diet
AST ALT TB
mg/dllU/liter
VH 158 13
(7)
42 5
(7)
0.67 0.07
(7)
CsAl5mg 11O±9
(7)
27±2
(7)
0.97±0.11
(6)
CsGl5mg 1l3±9a
(6)
28±2
(6)
0.96±0.09
(5)
Data are mean SEM; Number of rats are in parentheses. Abbrevi-
ations are: AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase; TB, total bilirubin.
a p < 0.05 vs. VH
renal transplantation have also suggested less nephrotoxicity
for CsG than CsA as measured by serum creatinine and inulin
clearance [9—111.
Probably more important than the preservation of GFR was
the finding of considerably less cortical and medullary histolog-
ical injury in CsG rats as compared to CsA. Other experimental
studies in rats and rabbits also found less interstitial fibrosis
with CsG [1, 8]. There are no clinical data available yet for
comparison. Progressive renal failure and chronic striped inter-
stitial fibrosis have been described in solid organ transplanta-
tion and in patients with autoimmune diseases receiving CsA
[27—29]. The renal dysfunction occurs even with low cyclospo-
rine dosage and may be progressive despite drug dose reduction
[30—32]. The experimental model used in the present study
reproduces the pattern of striped interstitial fibrosis described
in patients receiving CsA. Elzinga, Rosen and Bennett showed
in this model that the tubulointerstitial injury progressed despite
withdrawal of CsA [22]. If our experimental findings are con-
firmed by the ongoing clinical trials, CsG may become an
important alternative for long-term transplant and non-
transplant immunosuppression.
CsA induced significant NAG enzymuria and a high FEK in
presence of very low FENa and levels of serum potassium
similar to that found im placebo rats, suggesting a distal tubule
lesion [33, 34]. In contrast CsG-treated rats had urinary excre-
tion of NAG and FEK similar to control animals. Both cyclo-
sponnes induced hypomagnesemia and an inappropriately high
fractional excretion of magnesium, supporting the concept that
the decrease in serum magnesium is not related with the
changes in GFR [35].
Since CsG has shown immunosuppressive activity equivalent
to CsA at dosages lower than those used in this study, the
occurrence of less nephrotoxicity with CsG suggests that the
mechanisms of cyclosporine toxicity and immunosuppression
may be independent. However, we did not do a direct compar-
ison between CsA and CsG immunosuppressive efficacy, and it
remains possible that decreased renal toxicity and decreased
immunosuppressive activities co-exist at these doses. Presently
it is not clear why CsG is less nephrotoxic. One possible
explanation might be related to differences in drug metabolism,
but CsG metabolites have structures consistent with those
identified for CsA [36]. Both drugs bound to cyclophilin equally
[37]. Although the pharmacokinetics of the two drugs was
clearly different, CsG was still less nephrotoxic when equiva-
Table 5. Pharmacokinetics of CsA and CsG after an intravenous
injection of cyclosporine 15 mg/kg, and tissue levels of CsA and CsG
after 3 weeks of cyclosporine treatment (15 mg/kg) on rice diet
CsA (6) CsG (7) P
Cs blood level after 24 hr 984 62 552 45 0.0002
ng/ml
Area under the curve 58.3 3.4 39.5 1.7 0.002
mg x hr/liter
Cs clearance ml/min/kg 4.3 0.3 6.4 0.3 0.0001
t½ hr 11.1 1.0 11.0 0.5 0.98
Vd liter/kg 4.0 0.1 6.2 0.3 0.0001
Cs kidney level after 3 weeks 33.7 l.6a 8.6 0.8a 0.0001
ng/mg
Cs liver level after 3 weeks 39.8 42b 17.3 2.5a 0.0035
ng/mg
Data are: mean 5EM; Number of rats are in parentheses. Abbrevi-
ations are: Cs, cyclosporine; t½, half-life; Vd, volume of distribution.N 4
bN.... 5
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1440
Fig. 3. Cyclosporine blood levels (CSBL) after an intravenous injec-
tion of CsA (0) or CsG (. 15 mg/kg (results are mean SEM). *P <
0.01, CsA vs. CsG.
lent blood levels of the two drugs were achieved by lowering
CsA dosage or when the CsG dose was increased to three times
the CsA dosage. However, while CsA induced similar renal and
hepatic contents of cyclosponne, the renal amount of CsG was
half of the liver CsG content. Rayat et al found that more CsG
than CsA was required to displace 3H-CsA from human periph-
eral blood mononuclear cells [38]. Thus, it is possible that CsG
and CsA have different cellular uptakes that would explain in
part the distinct toxicological pattern of the two drugs. There is
a single study showing that CsA but not CsG reduced PGE2
production in cultured rat mesangial cells [39].
Hepatotoxicity disclosed by increased serum bilirubin and
elevation in liver enzymes has been reported in experimental
animals receiving CsA or CsG [3, 13, 18, 28]. Results from
clinical trials are controversial. Huser et al reported increased
bilirubin, increased liver enzymes and abnormal liver histology
in three CsG-treated patients that improved after discontinua-
tion of the drug [19]. However, in larger series of CsG-treated
patients only slight elevations in liver enzymes were observed
[9—11]. Both drugs were toxic in vitro to human hepatoblastoma
*
* *
*
*
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cells [40]. In the present study there was a clear trend to
increased serum bilirubin with either CsA or CsG, but liver
enzymes and liver histology were normal. It is not clear why the
liver enzymes in CsA and CsG-treated animals were below the
values found for control rats.
Conflicting results have also been reported comparing the
pharmacokinetics of CsG and CsA. The variations are likely
related to differences in animal species and strain. In rats,
similar [3, 8, 16], lower [12, 41], and higher [7, 15] trough CsG
blood levels as compared to CsA were observed. Pharmacoki-
netic studies in rabbits were consistent with the results found in
our study, showing faster elimination and lower blood levels for
CsG [1, 42]. In this study, even increasing the dose of CsG from
15 to 25 mg/kg we did not observe an increased blood level of
the drug. In dogs CsG blood levels are higher and CsG
clearance lower as compared to CsA [43]. In humans, the first
published study suggested similar pharmacokinetics for CsA
and CsG [44], but subsequent studies showed that at equivalent
doses cyclosporine blood levels were higher with CsG [9—11,
19].
In summary, CsG induced less tubulointerstitial injury and
less glomerular and tubular dysfunction than CsA when the two
drugs were given in equivalent dosages by weight or when
similar trough blood levels of both drugs were achieved. These
findings are only partially explained due to differences in
pharmacokinetics and suggest innate differences in tissue up-
take and nephrotoxic potential of the two drugs. Other media-
tors of cyclosporine nephrotoxicity must be studied in experi-
mental animals as well as in humans given CsG in order to
clarify the mechanisms and implications of these results.
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